Angela Mastronuzzi, Head of Neuro-Oncology Unit at Bambino Gesù Children’s Hospital and President of AIEOP, shared a post on LinkedIn about a paper she co-authored with colleagues, published in Discover Oncology:
“Epigenomic characterization and therapeutic challenges of melanoma arising in giant nevi in pediatric patients – just published with Discover Oncology by Springer Nature.
Background: Congenital giant melanocytic nevi (CGMN) are rare melanocytic proliferations present at birth, associated with an increased risk of pediatric malignant melanoma (MM). Melanomas arising within CGMN are uncommon but clinically aggressive, with diagnostic challenges due to overlapping histopathological features with benign proliferations. This case series explores the clinicopathologic, molecular, and therapeutic profiles of three pediatric patients with MM arising in CGMN.
Conclusion: MM arising within CGMN poses diagnostic and therapeutic challenges. While molecular and epigenomic profiling supports accurate classification and understanding of disease biology, the role of immunotherapy remains uncertain – marked by reduced efficacy and significant immune-related toxicity. A multidisciplinary approach is essential to guide management and improve outcomes in this rare pediatric malignancy.
With special thanks to Il Coraggio Dei Bambini Foundation.”
Title: Epigenomic characterization and therapeutic challenges of melanoma arising in giant nevi in pediatric patients
Authors: Evelina Miele, Sabrina Rossi, Alessandra Stracuzzi, Sara Patrizi, Sabina Barresi, Marta Cajozzo, Lucia Pedace, Isabella Giovannoni, Fabio Dell’Otto, Andrea Diociaiuti, Francesca Grussu, Flavia Vinciarelli, Alessandro Crocoli, Aurora Castellano, Maria Carmen Garganese, Angela Mastronuzzi, Franco Locatelli, Rita Alaggio, May El Hachem, Mario Zama, Maria Debora De Pasquale
You can read the Full Article in Discover Oncology.
More posts featuring Angela Mastronuzzi.